Becton, Dickinson and Company (NYSE:BDX) Position Lessened by Farther Finance Advisors LLC

Farther Finance Advisors LLC trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,200 shares of the medical instruments supplier’s stock after selling 406 shares during the period. Farther Finance Advisors LLC’s holdings in Becton, Dickinson and Company were worth $530,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company during the third quarter worth $26,000. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth $45,000. Abound Wealth Management raised its holdings in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC raised its holdings in shares of Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 185 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Evercore ISI increased their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus increased their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Raymond James lowered their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Trading Up 1.2 %

Shares of NYSE:BDX opened at $240.10 on Thursday. The company has a market cap of $69.40 billion, a P/E ratio of 49.40, a P/E/G ratio of 1.76 and a beta of 0.43. The stock’s 50-day moving average is $237.53 and its 200-day moving average is $235.16. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $259.33. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.